While two mega-suitors battled over Synthes, the Swiss medical giant was busy boosting sales and reporting health growth in earnings.
Synthes saw 11 percent growth in revenues during the three months ended June 30, posting $992 million in sales compared to $892 million during the same period last year.
While the company doesn’t break down its financials further for the quarter, its six-month report shows 7 percent growth in earnings to $454 million, or $3.83 per diluted share, compared to $425 million, or $3.58 per diluted share during the first half of 2010.
[sead]
